{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:01:32Z","timestamp":1774987292387,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,7]],"date-time":"2017-08-07T00:00:00Z","timestamp":1502064000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s40264-017-0586-2","type":"journal-article","created":{"date-parts":[[2017,8,7]],"date-time":"2017-08-07T15:50:40Z","timestamp":1502121040000},"page":"77-86","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2520-5673","authenticated-orcid":false,"given":"Daniel","family":"Caldeira","sequence":"first","affiliation":[]},{"given":"Filipe B.","family":"Rodrigues","sequence":"additional","affiliation":[]},{"given":"Marta M.","family":"Duarte","sequence":"additional","affiliation":[]},{"given":"Carmelo","family":"Sterrantino","sequence":"additional","affiliation":[]},{"given":"M\u00e1rcio","family":"Barra","sequence":"additional","affiliation":[]},{"given":"Nilza","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"Fausto J.","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Costa","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,8,7]]},"reference":[{"issue":"5","key":"586_CR1","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s11096-015-0144-x","volume":"37","author":"HJ Yang","year":"2015","unstructured":"Yang HJ, Ryoo JY, Yoo BK. Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection. Int J Clin Pharm. 2015;37(5):698\u2013708.","journal-title":"Int J Clin Pharm"},{"key":"586_CR2","unstructured":"US Department of Health and Human Services. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another Direct Acting Antiviral drug. Silver Spring, MD: 2015; US FDA. \n                        http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm439484.htm\n                        \n                    . Accessed Mar 2017."},{"issue":"6","key":"586_CR3","doi-asserted-by":"crossref","first-page":"1378.e1","DOI":"10.1053\/j.gastro.2015.07.051","volume":"149","author":"S Renet","year":"2015","unstructured":"Renet S, Chaumais MC, Antonini T, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology. 2015;149(6):1378.e1\u20131380.e1.","journal-title":"Gastroenterology"},{"issue":"19","key":"586_CR4","first-page":"1888","volume":"373","author":"DM Brainard","year":"2015","unstructured":"Brainard DM, McHutchison JG. Bradyarrhythmias associated with sofosbuvir treatment. N Engl J Med. 2015;373(19):1888.","journal-title":"N Engl J Med"},{"issue":"4","key":"586_CR5","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65\u201394.","journal-title":"Ann Intern Med"},{"key":"586_CR6","doi-asserted-by":"crossref","first-page":"i157","DOI":"10.1136\/bmj.i157","volume":"352","author":"L Zorzela","year":"2016","unstructured":"Zorzela L, Loke YK, Ioannidis JP, et al. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ. 2016;352:i157.","journal-title":"BMJ"},{"issue":"19","key":"586_CR7","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMc1505967","volume":"373","author":"H Fontaine","year":"2015","unstructured":"Fontaine H, Lazarus A, Pol S, et al. Bradyarrhythmias associated with sofosbuvir treatment. N Engl J Med. 2015;373(19):1886\u20138.","journal-title":"N Engl J Med"},{"issue":"6","key":"586_CR8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/016555150102700601","volume":"27","author":"VJ White","year":"2001","unstructured":"White VJ, Glanville JM, Lefebvre C, et al. A statistical approach to designing search filters to find systematic reviews: objectivity enhances accuracy. J Inf Sci. 2001;27(6):357\u201370.","journal-title":"J Inf Sci."},{"issue":"2","key":"586_CR9","first-page":"130","volume":"94","author":"JM Glanville","year":"2006","unstructured":"Glanville JM, Lefebvre C, Miles JN, et al. How to identify randomized controlled trials in MEDLINE: ten years on. J Med Libr Assoc. 2006;94(2):130\u20136.","journal-title":"J Med Libr Assoc"},{"key":"586_CR10","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. 5.1.0 ed. New York: Wiley; 2011.","edition":"5.1.0"},{"issue":"11","key":"586_CR11","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/sim.1188","volume":"21","author":"JJ Deeks","year":"2002","unstructured":"Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med. 2002;21(11):1575\u2013600.","journal-title":"Stat Med"},{"issue":"11","key":"586_CR12","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"issue":"9","key":"586_CR13","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","volume":"23","author":"MJ Sweeting","year":"2004","unstructured":"Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23(9):1351\u201375.","journal-title":"Stat Med"},{"issue":"1","key":"586_CR14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","volume":"26","author":"MJ Bradburn","year":"2007","unstructured":"Bradburn MJ, Deeks JJ, Berlin JA, et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26(1):53\u201377.","journal-title":"Stat Med"},{"issue":"498","key":"586_CR15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/01621459.2012.664484","volume":"107","author":"DK Bhaumik","year":"2012","unstructured":"Bhaumik DK, Amatya A, Normand SL, et al. Meta-analysis of rare binary adverse event data. J Am Stat Assoc. 2012;107(498):555\u201367.","journal-title":"J Am Stat Assoc"},{"issue":"5","key":"586_CR16","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/jth.12544","volume":"12","author":"D Caldeira","year":"2014","unstructured":"Caldeira D, David C, Santos AT, et al. Efficacy and safety of low molecular weight heparin in patients with mechanical heart valves: systematic review and meta-analysis. J Thromb Haemost. 2014;12(5):650\u20139.","journal-title":"J Thromb Haemost"},{"issue":"20","key":"586_CR17","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/sim.3964","volume":"29","author":"T Cai","year":"2010","unstructured":"Cai T, Parast L, Ryan L. Meta-analysis for rare events. Stat Med. 2010;29(20):2078\u201389.","journal-title":"Stat Med"},{"issue":"7","key":"586_CR18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2288-7-5","volume":"23","author":"JO Friedrich","year":"2007","unstructured":"Friedrich JO, Adhikari NK, Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol. 2007;23(7):5.","journal-title":"BMC Med Res Methodol"},{"issue":"353","key":"586_CR19","doi-asserted-by":"crossref","first-page":"i2089","DOI":"10.1136\/bmj.i2089","volume":"30","author":"P Alonso-Coello","year":"2016","unstructured":"Alonso-Coello P, Oxman AD, Moberg J, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ. 2016;30(353):i2089.","journal-title":"BMJ"},{"issue":"353","key":"586_CR20","doi-asserted-by":"crossref","first-page":"i2016","DOI":"10.1136\/bmj.i2016","volume":"28","author":"P Alonso-Coello","year":"2016","unstructured":"Alonso-Coello P, Schunemann HJ, Moberg J, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016;28(353):i2016.","journal-title":"BMJ"},{"issue":"4","key":"586_CR21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401\u20136.","journal-title":"J Clin Epidemiol"},{"issue":"20","key":"586_CR22","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","volume":"368","author":"IM Jacobson","year":"2013","unstructured":"Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867\u201377.","journal-title":"N Engl J Med"},{"issue":"20","key":"586_CR23","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","volume":"368","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878\u201387.","journal-title":"N Engl J Med"},{"issue":"21","key":"586_CR24","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993\u20132001.","journal-title":"N Engl J Med"},{"issue":"4","key":"586_CR25","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1473-3099(15)70050-2","volume":"15","author":"M Bourliere","year":"2015","unstructured":"Bourliere M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir\u2013sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15(4):397\u2013404.","journal-title":"Lancet Infect Dis"},{"issue":"27","key":"586_CR26","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599\u2013607.","journal-title":"N Engl J Med"},{"issue":"6","key":"586_CR27","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2016.07.050","volume":"65","author":"J Sperl","year":"2016","unstructured":"Sperl J, Horvath G, Halota W, et al. Efficacy and safety of elbasvir\/grazoprevir and sofosbuvir\/pegylated interferon\/ribavirin: a phase III randomized controlled trial. J Hepatol. 2016;65(6):1112\u20139.","journal-title":"J Hepatol"},{"issue":"14","key":"586_CR28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1471-230X-14-65","volume":"05","author":"A Josefsson","year":"2014","unstructured":"Josefsson A, Fu M, Bjornsson E, et al. Prevalence of pre-transplant electrocardiographic abnormalities and post-transplant cardiac events in patients with liver cirrhosis. BMC Gastroenterol. 2014;05(14):65.","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"586_CR29","doi-asserted-by":"crossref","first-page":"662","DOI":"10.4254\/wjh.v7.i4.662","volume":"7","author":"I Mozos","year":"2015","unstructured":"Mozos I. Arrhythmia risk in liver cirrhosis. World J Hepatol. 2015;7(4):662\u201372.","journal-title":"World J Hepatol"},{"issue":"11","key":"586_CR30","doi-asserted-by":"crossref","first-page":"e0142937","DOI":"10.1371\/journal.pone.0142937","volume":"10","author":"AJ Karajamaki","year":"2015","unstructured":"Karajamaki AJ, Patsi OP, Savolainen M, et al. Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA Study). PLoS One. 2015;10(11):e0142937.","journal-title":"PLoS One"},{"issue":"5","key":"586_CR31","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1007\/s10620-016-4040-6","volume":"61","author":"A Mantovani","year":"2016","unstructured":"Mantovani A, Ballestri S, Lonardo A, et al. Cardiovascular disease and myocardial abnormalities in nonalcoholic fatty liver disease. Dig Dis Sci. 2016;61(5):1246\u201367.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"586_CR32","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2013.09.016","volume":"60","author":"PS Ge","year":"2014","unstructured":"Ge PS, Runyon BA. The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol. 2014;60(3):643\u201353.","journal-title":"J Hepatol"},{"issue":"6","key":"586_CR33","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1053\/j.gastro.2015.09.031","volume":"149","author":"DJ Back","year":"2015","unstructured":"Back DJ, Burger DM. Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology. 2015;149(6):1315\u20137.","journal-title":"Gastroenterology"},{"key":"586_CR34","unstructured":"US Department of Health and Human Services. US Food and Drug Administration. FDA Hepatitis Update\u2014Important safety information: Harvoni, and Sovaldi. Silver Spring, MD: US FDA; 2015. \n                        http:\/\/content.govdelivery.com\/accounts\/USFDA\/bulletins\/f97c71\n                        \n                    . Accessed Mar 2017."},{"issue":"5","key":"586_CR35","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28752","volume":"64","author":"CP Regan","year":"2016","unstructured":"Regan CP, Morissette P, Regan HK, et al. Assessment of the clinical cardiac drug\u2013drug interaction associated with the combination of hepatitis C virus nucleotide inhibitors and amiodarone in guinea pigs and rhesus monkeys. Hepatology. 2016;64(5):1430\u201341.","journal-title":"Hepatology"},{"issue":"1","key":"586_CR36","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/toxsci\/kfw153","volume":"154","author":"DC Millard","year":"2016","unstructured":"Millard DC, Strock CJ, Carlson CB, et al. Identification of drug\u2013drug interactions in vitro: a case study evaluating the effects of sofosbuvir and amiodarone on hiPSC-derived cardiomyocytes. Toxicol Sci. 2016;154(1):174\u201382.","journal-title":"Toxicol Sci"},{"key":"586_CR37","series-title":"Cochrane book series","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/9780470712184.ch16","volume-title":"Special topics in statistics. Cochrane handbook for systematic reviews of interventions","author":"J Higgins","year":"2008","unstructured":"Higgins J, Deeks JJ, Altman DG. Special topics in statistics. Cochrane handbook for systematic reviews of interventions. Cochrane book series. New York: Wiley; 2008, p. 481\u2013529."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-017-0586-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0586-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0586-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T10:54:07Z","timestamp":1515581647000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-017-0586-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["586"],"URL":"https:\/\/doi.org\/10.1007\/s40264-017-0586-2","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,7]]}}}